Stock LEQ.H LEO ACQUISITIONS CORP
Add to a list
To use this feature you must be a member
Log inSign up

Financials Leo Acquisitions Corp Toronto S.E.

Equities

LEQ.H

CA5263612098

Biotechnology & Medical Research

End-of-day quote Toronto S.E.
Other stock markets
 06:00:00 2023-11-23 pm EST 		5-day change 1st Jan Change
0.01 CAD +33.33% Intraday chart for Leo Acquisitions Corp -.--% -.--%
2021 PsyBio Therapeutics Files Patent Application with USPTO for Production Methods of Methylated Trypatamines and Associated Analogs CI
2021 PsyBio Therapeutics : Files Novel Psychedelic Compositions and Methods of Treatment Patent With USPTO MT

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 17.87 2.874
Enterprise Value (EV) 1 14.06 3.009
P/E ratio -1.54 x -0.59 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA - -693,581 x
EV / FCF -3,823,542 x -2,125,619 x
FCF Yield -0% -0%
Price to Book 6.57 x -1.81 x
Nbr of stocks (in thousands) 112,961 111,338
Reference price 2 0.1582 0.0258
Announcement Date 3/2/22 4/28/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales - - -
EBITDA - - -4.338
EBIT 1 -6.436 -9.043 -4.49
Operating Margin - - -
Earnings before Tax (EBT) 1 -6.436 -11.02 -4.886
Net income 1 -6.436 -11.02 -4.886
Net margin - - -
EPS - -0.1030 -0.0437
Free Cash Flow - -3.678 -1.415
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 2/17/21 3/2/22 4/28/23
1USD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales 1 - - - - -
EBITDA - - - - -
EBIT 1 -4.755 -2.95 -2.596 -1.884 -1.813
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -4.756 -2.914 -3.014 -2.006 -1.868
Net income 1 -4.933 -2.733 -3.014 -2.006 -1.868
Net margin - - - - -
EPS - - - - -
Dividend per Share - - - - -
Announcement Date 8/30/21 11/29/21 3/2/22 5/30/22 8/29/22
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt 1 - - 0.13
Net Cash position 1 0.27 3.81 -
Leverage (Debt/EBITDA) - - -0.031 x
Free Cash Flow - -3.68 -1.42
ROE (net income / shareholders' equity) - -1,113% -867%
ROA (Net income/ Total Assets) - -263% -128%
Assets 1 - 4.187 3.829
Book Value Per Share 2 -0.0100 0.0200 -0.0100
Cash Flow per Share 2 0.0100 0 0
Capex - - -
Capex / Sales - - -
Announcement Date 2/17/21 3/2/22 4/28/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.46% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 96.29B
ARGENX SE Stock argenx SE
+2.13% 22.18B
BIONTECH SE Stock BioNTech SE
-15.84% 21.2B
GENMAB A/S Stock Genmab A/S
-9.21% 18.31B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.38B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.65% 16.36B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.39% 13.97B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+31.35% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PSYB.H Stock
  4. LEQ.H Stock
  5. Financials Leo Acquisitions Corp